CHCarole Henry

Carole Henry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carole Henry has a total of 209 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick C. Wilson

    Drukier Institute for Children’s Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA

    9 shared publications
  • Min Huang

    Department of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA

    5 shared publications
  • Nai-Ying Zheng

    Department of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA

    5 shared publications
  • Anna-Karin E. Palm

    Section of Immunology, Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, SE-751 23 Uppsala, Sweden

    4 shared publications
  • Florian Krammer

    Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

    3 shared publications
  • Henry A. Utset

    Department of Medicine, Section of Rheumatology, University of Chicago, Chicago, IL 60637, USA

    3 shared publications

Latest Publications

  • Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2

    by Guillaume B. E. Stewart-Jones, Sayda M. Elbashir, Kai Wu, Diana Lee, Isabella Renzi, Baoling Ying, Matthew Koch, Caralyn E. Sein, Angela Choi, Bradley Whitener, et al.

    With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines encoding the wild-type spike protein receptor binding domain (RBD) or N-terminal domain (NTD) alone or in combination. An NTD-RBD–linked candidate vaccine, mRNA-1283, showed improved antigen expression, antibody responses, and stability at refrigerated temperatures (2° to 8°C) compared with the clinically available mRNA-1273, which encodes the full-length spike protein. In BALB/c mice administered mRNA-1283 as a primary series, booster, or variant-specific booster, similar or greater immune responses from viral challenge were observed against wild-type, beta, delta, or omicron (BA.1) viruses compared with mRNA-1273–immunized mice, especially at lower vaccine dosages. K18-hACE2 mice immunized with mRNA-1283 or mRNA-1273 as a primary series demonstrated similar degrees of protection from challenge with SARS-CoV-2 Delta and Omicron variants at all vaccine dosages. These results support clinical assessment of mRNA-1283, which has now entered clinical trials (NCT05137236).


  • Une dame de fer

    by Y. Dawudi, C. Henry

  • Open Access

    An egg-derived sulfated N-Acetyllactosamine glycan is an antigenic decoy of influenza virus vaccines

    by Jenna J. Guthmiller, Henry A. Utset, Carole Henry, Lei Li, Nai-Ying Zheng, Weina Sun, Marcos Costa Vieira, Seth Zost, Min Huang, Scott E. Hensley, et al.

    Influenza viruses grown in eggs for the purposes of vaccine generation often acquire mutations during egg adaptation or possess differential glycosylation patterns than viruses circulating amongst humans. Here, we report that seasonal influenza virus vaccines possess an egg-derived sulfated N-acetyllactosamine (LacNAc) that is an antigenic decoy. Half of subjects that received an egg-grown vaccine mounted an antibody response against this egg-derived antigen. Egg-binding monoclonal antibodies specifically bind viruses grown in eggs, but not viruses grown in other chicken derived cells, suggesting only egg-grown vaccines can induce anti-LacNAc antibodies. Notably, antibodies against the sulfated LacNAc utilized a restricted antibody repertoire and possessed features of natural antibodies, as most antibodies were IgM and have simple heavy chain complementarity determining region 3. By analyzing a public dataset of influenza virus vaccine induced plasmablasts, we discovered egg-binding public clonotypes that were shared across studies. Together, this study shows that egg-grown vaccines can induce antibodies against an egg-associated glycan, which may divert the host immune response away from protective epitopes.


  • Open Access

    A public broadly neutralizing antibody class targets a membrane-proximal anchor epitope of influenza virus hemagglutinin

    by Jenna J. Guthmiller, Julianna Han, Henry A. Utset, Lei Li, Linda Yu-Ling Lan, Carole Henry, Christopher T. Stamper, Olivia Stovicek, Lauren Gentles, Haley L. Dugan, et al.

    Summary: Broadly neutralizing antibodies against influenza virus hemagglutinin (HA) have the potential to provide universal protection against influenza virus infections. Here, we report a distinct class of broadly neutralizing antibodies targeting an epitope toward the bottom of the HA stalk domain where HA is “anchored” to the viral membrane. Antibodies targeting this membrane-proximal anchor epitope utilized a highly restricted repertoire, which encode for two conserved motifs responsible for HA binding. Anchor targeting B cells were common in the human memory B cell repertoire across subjects, indicating pre-existing immunity against this epitope. Antibodies against the anchor epitope at both the serological and monoclonal antibody levels were potently induced in humans by a chimeric HA vaccine, a potential universal influenza virus vaccine. Altogether, this study reveals an underappreciated class of broadly neutralizing antibodies against H1-expressing viruses that can be robustly recalled by a candidate universal influenza virus vaccine.


  • Open Access

    In situ humoral selection in human lupus tubulointerstitial inflammation

    by Andrew J Kinloch, Yuta Asano, Azam Mohsin, Carole J Henry, Rebecca Abraham, Anthony Chang, Christine Labno, Patrick C Wilson, Marcus R Clark

    In human lupus nephritis, tubulointerstitial inflammation (TII) is associated with in situ expansion of B cells expressing anti-vimentin antibodies (AVAs). The mechanism by which AVAs are selected is unclear. Herein, we demonstrate that AVA somatic hypermutation and selection increase affinity for vimentin. However, enzyme-linked immunosorbent assays (ELISAs) suggested that affinity maturation might be a non-specific consequence of increasing polyreactivity. Subsequent multi-color confocal microscopy studies indicated that while TII AVAs often appeared polyreactive by ELISA, they bound selectively to vimentin fibrils in whole cells or inflamed renal tissue. Using a novel machine learning pipeline (CytoSkaler) to quantify the cellular distribution of antibody staining, we demonstrated that TII AVAs were selected for both enhanced binding and specificity in situ . These data suggest a new approach to assess and define antibody polyreactivity based on quantifying the distribution of binding to native and contextually relevant antigens.


  • Open Access

    Characterizing Emerging Canine H3 Influenza Viruses

    by Luis Martinez-Sobrido, Pilar Blanco-Lobo, Laura Rodriguez, Theresa Fitzgerald, Hanyuan Zhang, Phuong Nguyen, Christopher S Anderson, Jeanne Holden-Wiltse, Sanjukta Bandyopadhyay, Aitor Nogales, et al.

    The continual emergence of novel influenza A strains from non-human hosts requires constant vigilance and the need for ongoing research to identify strains that may pose a human public health risk. Since 1999, canine H3 influenza A viruses (CIVs) have caused many thousands or millions of respiratory infections in dogs in the United States. While no human infections with CIVs have been reported to date, these viruses could pose a zoonotic risk. In these studies, the National Institutes of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) network collaboratively demonstrated that CIVs replicated in some primary human cells and transmitted effectively in mammalian models. While people born after 1970 had little or no pre-existing humoral immunity against CIVs, the viruses were sensitive to existing antivirals and we identified a panel of H3 cross-reactive human monoclonal antibodies (hmAbs) that could have prophylactic and/or therapeutic value. Our data predict these CIVs posed a low risk to humans. Importantly, we showed that the CEIRS network could work together to provide basic research information important for characterizing emerging influenza viruses, although there were valuable lessons learned. The 2009 influenza pandemic was a stark reminder that ongoing vigilance is critical to protect the public from an influenza pandemic. The continual evolution of influenza viruses and emergence from animal reservoirs, leads to the need to quickly identify strains that pose a public health risk. In these studies, members of the National Institutes of Allergy and Infectious Diseases (NIAID) Centers for Excellence in Influenza Research and Surveillance (CEIRS) network worked together to demonstrate that the emerging canine H3 influenza viruses posed a low risk to public health and identified several therapeutic options in the event of an emergence. In addition to providing important new basic research, many lessons were learned that may be important in dealing with any emerging disease outbreak.


  • Aging and influenza vaccine-induced immunity

    by Haley L. Dugan, Carole Henry, Patrick C. Wilson


  • RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome

    by Baptiste Abbar, Carole Henry, Nathalie Theou-Anton, Solenn Brosseau, Marina Nguenang, Johan Pluvy, Sandra Assoun, Gérard Zalcman, Valérie Gounant


  • Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study

    by Carole Henry, Anna-Karin E Palm, Henry A Utset, Min Huang, Irvin Y Ho, Nai-Ying Zheng, Theresa Fitzgerald, Karlynn E Neu, Yao-Qing Chen, Florian Krammer, et al.

    There are ongoing efforts to increase the efficacy of influenza vaccines and to promote production strategies that can rapidly respond to newly emerging viruses. It is important to understand if current alternative seasonal vaccines, such as Flublok and Flucelvax, that use alternate production strategies can induce protective influenza-specific antibodies and to evaluate what type of epitopes are targeted by distinct vaccine formulations.